[25-NSE] LIPELLA PHARMACEUTICALS INC. SEC Filing
Lipella Pharmaceuticals, Inc. submitted a Form 25 notification indicating that a class of its securities will be removed from listing and/or registration on the Nasdaq Stock Market LLC.
Nasdaq certifies it has reasonable grounds to file the Form 25 and indicates compliance with the applicable Exchange rules and with 17 CFR 240.12d2-2 provisions for withdrawal or removal. The filing supplies issuer contact details in Pittsburgh but does not disclose timing, reason, or financial effects of the removal.
Lipella Pharmaceuticals, Inc. ha presentato una notifica Form 25 indicando che una classe dei suoi titoli sarà rimossa dall'elenco e/o dalla registrazione sul Nasdaq Stock Market LLC.
Nasdaq certifica di avere motivi ragionevoli per presentare il Form 25 e indica conformità alle normative di scambio applicabili e alle disposizioni di 17 CFR 240.12d2-2 per la revoca o rimozione. La presentazione fornisce dettagli di contatto dell'emittente a Pittsburgh ma non comunica il tempo, la ragione o gli effetti finanziari della rimozione.
Lipella Pharmaceuticals, Inc. presentó una notificación Form 25 indicando que una clase de sus valores será removida de la cotización y/o registro en Nasdaq Stock Market LLC.
Nasdaq certifica que tiene motivos razonables para presentar el Form 25 e indica cumplimiento de las reglas del Exchange aplicables y de las disposiciones 17 CFR 240.12d2-2 para retirada o eliminación. La presentación proporciona datos de contacto del emisor en Pittsburgh, pero no divulga el momento, la razón o los efectos financieros de la retirada.
Lipella Pharmaceuticals, Inc.는 Nasdaq Stock Market LLC에서 증권의 한 종류를 상장 및/또는 등록에서 제거하겠다는 Form 25 통지를 제출했습니다.
Nasdaq은 Form 25를 제출할 합당한 사유가 있으며 적용 거래소 규칙 및 17 CFR 240.12d2-2 조항에 따른 철회 또는 제거를 준수한다고 인증합니다. 제출물은 피츠버그에 있는 발행사 연락처를 제공하지만 제거의 시기, 사유 또는 재정적 영향은 공개하지 않습니다.
Lipella Pharmaceuticals, Inc. a soumis un avis Form 25 indiquant qu'une catégorie de ses titres sera radiée de la cotation et/ou de l'enregistrement sur Nasdaq Stock Market LLC.
Nasdaq certifie avoir des motifs raisonnables pour déposer le Form 25 et indique le respect des règles d'échange applicables et des dispositions 17 CFR 240.12d2-2 relatives au retrait ou à la suppression. Le dépôt fournit des coordonnées de l'émetteur à Pittsburgh mais ne révèle ni le calendrier, ni la raison, ni les effets financiers du retrait.
Lipella Pharmaceuticals, Inc. hat eine Form 25-Mitteilung eingereicht, die angibt, dass eine Klasse ihrer Wertpapiere von der Notierung und/oder Registrierung an der Nasdaq Stock Market LLC entfernt wird.
Nasdaq bestätigt, dass es über hinreichende Gründe verfügt, das Form 25 einzureichen, und bestätigt die Einhaltung der anwendbaren Börsenregeln sowie der Bestimmungen gemäß 17 CFR 240.12d2-2 für den Rückzug oder die Entfernung. Die Einreichung enthält Kontaktdaten des Emittenten in Pittsburgh, offenbart jedoch nicht Zeitpunkt, Grund oder finanzielle Auswirkungen der Entfernung.
Lipella Pharmaceuticals, Inc. قدمت إشعار Form 25 يشير إلى أن فئة من سنداتها ستُزال من القيد والتسجيل في Nasdaq Stock Market LLC.
تقر ناسداك بأن لديها أسباباً معقولة لتقديم النموذج 25 وتشير إلى الامتثال لقواعد البورصة المعمول بها وأحكام 17 CFR 240.12d2-2 الخاصة بالانسحاب أو الإزالة. يزوّد الملف معلومات اتصال مصدر الإصدار في بيتسبرغ ولكنه لا يكشف عن التوقيت أو السبب أو الآثار المالية للإزالة.
Lipella Pharmaceuticals, Inc. 提交了 Form 25 通知，表明其一类证券将从纳斯达克交易所（Nasdaq Stock Market LLC）的挂牌和/或注册中被移除。
纳斯达克证实其有合理依据提交 Form 25，并表示遵守适用交易所规则以及 17 CFR 240.12d2-2 关于撤回或移除的规定。该申报提供了在匹兹堡的发行人联系方式，但未披露撤回的时间、原因或财政影响。
- Procedural compliance is documented with Nasdaq certifying adherence to 17 CFR 240.12d2-2
- Issuer contact details are provided, facilitating follow-up questions
- Removal from Nasdaq listing/registration is indicated, which is a material change to trading status
- No effective date or reason for the listing removal is disclosed, limiting investor assessment
- Class of securities not explicitly described in the text provided, reducing clarity on scope
Insights
Nasdaq removal notice filed; details on timing and reasons are not disclosed.
The document is a formal Form 25 notification that a class of Lipella Pharmaceuticals' securities will be struck from Nasdaq listing or its registration withdrawn. The notice states Nasdaq believes it has reasonable grounds for filing and cites compliance with 17 CFR 240.12d2-2 clauses.
Material dependencies are explicit: the filing confirms procedural compliance but omits timing, the specific class affected, and any financial or operational rationale. Investors should note the removal itself is material; the absence of dates or impacts limits ability to assess near-term effects.
Filing documents procedural compliance but provides no impact metrics or transaction details.
The filing records issuer contact information and a certification by Nasdaq that Exchange rules were followed for striking the securities or withdrawing registration. It also references the applicable regulatory provisions and standard Form 25 procedures.
Risks center on missing disclosures: there is no statement about whether the withdrawal is voluntary or involuntary, no effective date, and no commentary on outstanding shares or secondary trading. Those omissions constrain clarity on liquidity and governance effects in the near term.
Lipella Pharmaceuticals, Inc. ha presentato una notifica Form 25 indicando che una classe dei suoi titoli sarà rimossa dall'elenco e/o dalla registrazione sul Nasdaq Stock Market LLC.
Nasdaq certifica di avere motivi ragionevoli per presentare il Form 25 e indica conformità alle normative di scambio applicabili e alle disposizioni di 17 CFR 240.12d2-2 per la revoca o rimozione. La presentazione fornisce dettagli di contatto dell'emittente a Pittsburgh ma non comunica il tempo, la ragione o gli effetti finanziari della rimozione.
Lipella Pharmaceuticals, Inc. presentó una notificación Form 25 indicando que una clase de sus valores será removida de la cotización y/o registro en Nasdaq Stock Market LLC.
Nasdaq certifica que tiene motivos razonables para presentar el Form 25 e indica cumplimiento de las reglas del Exchange aplicables y de las disposiciones 17 CFR 240.12d2-2 para retirada o eliminación. La presentación proporciona datos de contacto del emisor en Pittsburgh, pero no divulga el momento, la razón o los efectos financieros de la retirada.
Lipella Pharmaceuticals, Inc.는 Nasdaq Stock Market LLC에서 증권의 한 종류를 상장 및/또는 등록에서 제거하겠다는 Form 25 통지를 제출했습니다.
Nasdaq은 Form 25를 제출할 합당한 사유가 있으며 적용 거래소 규칙 및 17 CFR 240.12d2-2 조항에 따른 철회 또는 제거를 준수한다고 인증합니다. 제출물은 피츠버그에 있는 발행사 연락처를 제공하지만 제거의 시기, 사유 또는 재정적 영향은 공개하지 않습니다.
Lipella Pharmaceuticals, Inc. a soumis un avis Form 25 indiquant qu'une catégorie de ses titres sera radiée de la cotation et/ou de l'enregistrement sur Nasdaq Stock Market LLC.
Nasdaq certifie avoir des motifs raisonnables pour déposer le Form 25 et indique le respect des règles d'échange applicables et des dispositions 17 CFR 240.12d2-2 relatives au retrait ou à la suppression. Le dépôt fournit des coordonnées de l'émetteur à Pittsburgh mais ne révèle ni le calendrier, ni la raison, ni les effets financiers du retrait.
Lipella Pharmaceuticals, Inc. hat eine Form 25-Mitteilung eingereicht, die angibt, dass eine Klasse ihrer Wertpapiere von der Notierung und/oder Registrierung an der Nasdaq Stock Market LLC entfernt wird.
Nasdaq bestätigt, dass es über hinreichende Gründe verfügt, das Form 25 einzureichen, und bestätigt die Einhaltung der anwendbaren Börsenregeln sowie der Bestimmungen gemäß 17 CFR 240.12d2-2 für den Rückzug oder die Entfernung. Die Einreichung enthält Kontaktdaten des Emittenten in Pittsburgh, offenbart jedoch nicht Zeitpunkt, Grund oder finanzielle Auswirkungen der Entfernung.
FAQ
What does the Form 25 filed by Lipella Pharmaceuticals (LIPO) announce?
Does the filing state when the Nasdaq removal becomes effective for LIPO?
Does the Form 25 explain why Lipella's securities are being removed?
Which regulatory provisions are cited in the Form 25 for LIPO's removal?
Who can investors contact for more information about the LIPO filing?
